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Background: Human artificial chromosome (HAC) vectors have some unique characteristics as compared with
conventional vectors, carrying large transgenes without size limitation, showing persistent expression of transgenes,
and existing independently from host genome in cells. With these features, HACs are expected to be promising
vectors for modifications of a variety of cell types. However, the method of introduction of HACs into target cells is
confined to microcell-mediated chromosome transfer (MMCT), which is less efficient than other methods of vector
introduction. Application of Measles Virus (MV) fusogenic proteins to MMCT instead of polyethylene glycol (PEG)
has partly solved this drawback, whereas the tropism of MV fusogenic proteins is restricted to human CD46- or
SLAM-positive cells.
Results: Here, we show that retargeting of microcell fusion by adding anti-Transferrin receptor (TfR) single chain
antibodies (scFvs) to the extracellular C-terminus of the MV-H protein improves the efficiency of MV-MMCT to human
fibroblasts which originally barely express both native MV receptors, and are therefore resistant to MV-MMCT. Efficacy
of chimeric fusogenic proteins was evaluated by the evidence that the HAC, tagged with a drug-resistant gene and
an EGFP gene, was transferred from CHO donor cells into human fibroblasts. Furthermore, it was demonstrated that no
perturbation of either the HAC status or the functions of transgenes was observed on account of retargeted MV-MMCT
when another HAC carrying four reprogramming factors (iHAC) was transferred into human fibroblasts.
Conclusions: Retargeted MV-MMCT using chimeric H protein with scFvs succeeded in extending the cell spectrum for
gene transfer via HAC vectors. Therefore, this technology could facilitate the systematic cell engineering by HACs.
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Microcell-mediated chromosome transfer (MMCT) is a
technique by which single or small numbers of chromo-
somes can be transferred from one mammalian cell to an-
other by microcell fusion [1-3]. This technique can move
the large intact genomic structures of natural chromo-
somes or artificially engineered chromosomes, and trans-
ferred chromosomes can be stably retained and freely* Correspondence: oshimura@med.tottori-u.ac.jp
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features, MMCT has been employed very successfully in
various basic science studies, e.g., genetic mapping and
identification of tumor suppressor genes, analysis of
genomic imprinting and production of animal models of
disease [4-7]. Furthermore, MMCT is also used in gene
transfer using a human artificial chromosome (HAC),
mini-chromosome vector. HACs have several unique
characteristics as gene-delivery vectors, including stable
episomal maintenance in mammalian cells, the capacity
to carry large transgenes, and less susceptibility to gene
silencing, and have been applied to gene therapy [8-10],article distributed under the terms of the Creative Commons Attribution
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and protein production [14-16].
In microcell fusion, protocols combining treatment of
cells with phytohemagglutinin-P (PHA-P) to adhere micro-
cells to recipient cells and fusion using polyethylene glycol
(PEG) are most common, because they have proved to be
more simple and efficient than those initially using inacti-
vated Sendai virus [17]. Nonetheless, a yield frequency of
microcell hybrids by PEG-induced fusion is no more than
1 × 10-6 – 1 × 10-5 [18]. Higher concentrations of PEG can
produce larger numbers of fused cells, but in the meantime
PEG cytotoxicity increased. Little is known about the
functional mechanism of PEG, but PEG may incur a redis-
tribution of intramembrane molecules within the plasma
membrane in a cell-type dependent fashion. Therefore, it
may be difficult to separate fusogenic function from cyto-
toxicity of PEG. To overcome the drawback of PEG-
induced microcell fusion, we have developed a novel
method for MMCT where Measles Virus (MV) envelope
proteins (MV-MMCT) are applied instead of using PHA-
P and PEG [19]. It was demonstrated that higher efficiency
of microcell fusion was achieved in some human cells by
means of microcells which expressed MV-derived fusion
machinery, both the hemagglutinin (H) protein and fusion
(F) protein, as compared to PEG-induced fusion. However,
the human fibroblast cell line HFL-1 did not exhibit sus-
ceptibility to MV-derived fusion machinery. Since cellular
tropism of MV is determined by binding of the H protein
to cell surface protein, CD46 or SLAM [20-22], in order
to extend the cell spectrum eligible for MV-MMCT, fur-
ther modification of MV-derived fusion machinery is
needed. It has been demonstrated that the tropism of MV
can be retargeted to many different cell surface molecules
by utilizing a fusion protein consisting of single-chain
antibodies (scFv), peptides, growth factors or cytokines
fused to the extracellular C terminus of the H protein
[23]. Furthermore, co-transfection of plasmids, encoding
the chimeric H protein fused to scFv which recognizes
muscle-specific integrin α7 and the F protein, into human
fibroblasts could induce fusion to differentiated mouse
myotubes without viral infection [24]. Therefore, consider-
ing that the complex of the chimeric H protein and the F
protein can induce whole cell fusion, we were keen to
study whether the chimeric H protein was also capable of
mediating microcell fusion.
Here we report a targeted MV-MMCT approach to
transfer a HAC vector from CHO donor cells into
normal human fibroblasts. The chimeric H protein was
produced by fusing anti-transferrin receptor (TfR) scFv
to the C-terminus of the H protein. Successfully, co-
transfection of plasmids encoding the chimeric H protein
and the F protein into CHO cells, which harbor the HAC
vector containing drug-resistant genes, GFP and the re-
programming gene cassette for human cells, followed byMMCT, induced microcell fusion to human HFL-1 cells.
Drug-resistant and GFP positive colonies were obtained
after drug selection, and introduction of the HAC vector
to HFL-1 cells was confirmed by FISH analysis. Trans-
genes from the reprogramming cassette were efficiently
transcribed, and subsequently dedifferentiation occurred
in some of these cells as we previously demonstrated in
the case of mouse cell reprogramming [25]. This result in-
dicated that targeted MV-derived fusion machinery had
no influence on HAC functions, in fact the intact HAC
could be transferred into recipient cells via targeted MV-
MMCT. Taken together, targeted MV-MMCT may be
powerful in extending the cell spectrum for gene transfer
via HAC vectors and/or chromosome transfer; so far
PEG-induced microcell fusion has been effective in only a
limited number of cell types.
Methods
Cell culture
Human fibrosarcoma (HT1080) cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma)
plus 10% fetal bovine serum (FBS). HFL-1 cells (RCB0521,
RIKEN, Tsukuba, Japan) were grown in Ham’s F12 medium
(Wako Pure Chemical Industries) supplemented with 15%
FBS. Hprt-deficient Chinese hamster ovary (CHO) cells
(JCRB0218, JCRB Cell Bank, Japan) containing the HAC
vector were cultured in Ham’s F-12 medium supple-
mented with 10% FBS and 8 μg/ml Blasticidin S (Bsd,
Funakoshi). HFL-1 cells introduced the HAC vector for
reprogramming (designated as iHAC) were maintained
on mitomycin-C (Kyowa Hakko Kirin)-treated SNL
(STO) feeder cells (SANGER Institute, Cambridge, UK)
in hES cell maintenance medium, which consisted of a
1:1 DMEM and Ham’s F-12 (Sigma) supplemented with
2 mM L-glutamine, 1 mM sodium pyruvate, 1% MEM
non-essential amino acids, 0.1 mM 2-mercaptoethanol
(Gibco), 4 ng/ml human basic fibroblast growth factor
(Wako Pure Chemical Industries) and 20% Knockout
serum replacement (Gibco).
Flow cytometry analysis
Cells were dispersed by treatment with 0.2% EDTA/PBS,
washed twice with PBS, and resuspended in ice-cold PBS
containing 2% (w/v) BSA at a concentration of 106 cells/
ml. The cells were then incubated for 60 min on ice with
a 1:50 final dilution of PE-labeled anti-TfR antibody (BD
Pharmingen), or PE-labeled isotype control (BD Pharmin-
gen). After washing with BSA/PBS, the cells were analyzed
with a Gallios flow cytometer (Beckman Coulter).
MV envelope protein expression plasmids and
transfection
DNA sequence encoding the scFv recognizing transfer-
rin receptor (TfR) was generated by PCR amplification,
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using the following primers: 5′-GCG GCC CAG CCG
GCC ATG G-3′ and 5′-CTT GCG GCC GCA CCT
AGG ACG GTC AGC TT-3′. The SfiI/NotI-digested
PCR products were subcloned into pTNH6-Haals [27] at
the corresponding restriction sites, resulting in pTNH6-
HaalsαTfR-#1-8, respectively (Additional file 1 Table S1).
A BsiWI-fragment of pCAG-T7F [19] was inserted into
the BsiWI site of pVITRO1-neo-mcs (InvivoGen), result-
ing in pVF#9. A BsrGI-fragment of pTNH6-HaalsαTfR-
#5 was inserted into the BsrGI site of pVF#9, resulting
in pVF#9-TfR.
Plasmids were linearized by restriction digestion with
PvuI (NEB) before transfection. HAC donor CHO cells
(8 × 104/well in 24-well plates (Nunc)) were co-transfected
with 0.3 μg each of pTNH6-H and pCAG-T7-F, and
0.25 μg of pDsRed-Monomer-N1 (Clontech) using Lipo-
fectamine 2000 (Invitrogen). At 24 h after transfection,
the cells were re-plated at low density and selected for
14 days with 800 μg/ml of G418 (Nacalai). Drug-resistant
cells were recovered as a mixed population. HT1080 cells
(2 × 106/6 cm dish) were co-transfected with 0.4 μg each
of pTNH6-H and pCAG-T7-F. After culture for 6 h, syn-
cytium formation was tested under the microscope.
Construction of HAC vectors for reprogramming (iHAC)
A SalI fragment of a human P53-knockdown construct
(pMKO.1 puro p53 shRNA2, Addgene) was cloned into the
SalI site of pinsB3 [25], resulting in pinsB3hP53sh. Finally,
an AscI-SpeI fragment of pinsB3hP53sh was inserted into
the AscI-NheI site of pPAC-2CAG-O2 (carrying two copies
of CAG-driven Klf4, c-Myc, Sox2, and four copies of CAG-
driven Oct4), resulting in pPAC-2CAG-O2hP53sh.
The reprogramming cassettes were introduced into
21HAC2 vectors [28] using the Cre-loxP system. Cre-
recombinase expression vectors (pBS185; Invitrogen)
(1 μg) and pPAC-2CAG-O2hP53sh (8 μg) were co-
transfected into CHO/21HAC2, which are Hprt-deficient
CHO (hprt-/-) cells carrying a 21HAC2, in a 60-mm dish
using Lipofectamine 2000. Recombinant clones were se-
lected using HAT (Sigma) and 8 μg/ml Bsd two days after
transfection. After 2 weeks, drug-resistant colonies with a
functional HPRT allele were identified by genomic PCR
and isolated. Next, quantitative RT-PCR analysis of re-
programming factors was performed. A CHO cell donor
clone that stably expressed reprogramming factors com-
parable to CHO/iHAC2 was selected and designated
CHO/iHAC/X53. FISH analysis showed that the iHAC
vector was maintained independently from the host
chromosomes in CHO/iHAC/X53.
Microcell fusion
Microcell fusion was performed as described previously
[19]. CHO4H6.1 M, CHO/21HAC2 and CHO/iHAC/X53 were used as microcell donor cells. Briefly, HT1080
or HFL-1 cells were fused with microcells prepared from
donor cells, and on the day following PEG fusion, the
cells were replated, and selected with 3 μg/ml of Bsd. In
the case of MV fusion, microcells were overlaid on re-
cipient cells and left for 24 h. After that, the cells were
replated, and cultured for 14 days in the presence of
3 μg/ml of Bsd.
FISH analysis
FISH analyses were performed using either fixed meta-
phase or interphase spreads of each cell hybrid using
digoxigenin-labeled (Roche) alphoid DNA probe p11-4
[29] and biotin-labeled (Roche) pPAC-2CAG-O2hP53sh,
essentially as described previously [30]. Chromosomal
DNA was counterstained with DAPI (Sigma). Images were
captured using the Axio Imager-Z2 (Carl Zeiss).
RT-PCR analysis
Total RNA was extracted with Trizol (Invitrogen) and
treated with a Turbo DNAfree kit (Ambion) to remove
genomic DNA contamination. cDNA was synthesized
using an oligo(dT) primer and ReverTra Ace (Toyobo).
Quantitative RT-PCR was performed using the Power
SYBR Green PCR Master Mix (Applied Biosystems) on
an ABI7900HT (Applied Biosystems). Semi-quantitative
RT-PCR was performed with cDNA using ExTaq (Takara
Bio). GAPDH and NAT1 were used as internal controls.
Primer sequences are listed in Additional file 1 Table S2.
Results
Construction and validation of Haals-αTfR
To explore applicability of MV-MMCT to human fibro-
blasts, TfR was selected as the target receptor in giving a
new directivity for MV-H protein, because TfR is known
to be ubiquitously expressed in all tissues [31]. Flow
cytometric analysis demonstrated that TfR was highly
expressed in both HFL-1 and HT1080 cells (Figure 1A),
whereas CD46 was expressed only in HT1080 cells, and
very rarely in HFL-1 cells [19]. Subsequently, recombin-
ant retargeted H proteins were constructed by using 8
clones of anti-TfR scFvs (Additional file 1 Table S1),
which recognized different epitopes of TfR, from the
phage-display antibody library [32]. Anti-TfR scFvs were
fused to the C terminus of a quadruple mutated H pro-
tein (Haals: Y481A, R533A, S548L and F549S), which
lacked the ability to bind both CD46 and SLAM [27,33],
to validate the effect of anti-TfR scFvs on cell fusion
more precisely (Figure 1B). To screen 8 constructs of
chimeric H proteins (Haals-αTfRs), we transfected expres-
sion plasmids encoding MV-F and Haals-αTfRs into
HT1080 cells and assayed syncytium formation by homo-
fusion. Sufficient formation of syncytia and syncytium-






















































Figure 1 Membrane-fusion activity of Haals-αTfR in recipient cells. (A) Detection of surface expression of target receptors in recipient cells. Surface
expression of TfR in HT1080 and HFL-1 cells was analyzed with flow cytometry by staining with PE-conjugated anti-TfR antibody (black peak) or
an isotype control (white peak). (B) Schematic representation of recombinant H protein. scFv is displayed as a C-terminal extension of H glycoprotein.
N; Amino-terminal cytoplasmic tail, TM; Transmembrane domain, *; Y481A, R533A, S548L and F549S mutations in H protein. (C) Syncytium formation
ability differed among scFv clones. HT1080 cells were co-transfected with F and indicated H expression plasmid, and were photographed 30 hr
later. (D) Fusion test by co-culture assay of donor and recipient cells. CHO cells stably expressing the F and H proteins were co-cultured with
HFL-1, and were photographed 24 hr later. Yellow arrows indicate syncytia. (E) The number of resistant/GFP(+) colonies from HFL-1 cells by
MV-MMCT using H or Haals-TfR. Data are the means of four independent experiments (±SD), **; p < 0.01 (unpaired t-test).
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in other clones (Figure 1C). Thus, clone No.5 (Haals-
αTfR-5) was selected for use in further experiments.
Next, we tested whether chimeric MV-H proteins con-
fer human fibroblast-directed fusion ability on CHO
cells. Expression vectors encoding the MV-F, Haals-αTfR-
5, and Neor were transfected into a CHO cell line contain-
ing 21HAC2 vector (CHO/21HAC2), and G418-resistant
cell population was pooled, which was designated as
CHO/21HAC2/TfR. As in the case with MV-F/H-trans-
fected CHO cells [19], co-transfection with MV-F and
Haals-αTfR-5 was unable to induce homofusion in CHO
cells (data not shown). On the other hand, co-culture of
these pooled CHO cells with HFL-1 cells caused forma-
tion of syncytium at higher frequency with the combin-
ation of MV-F/ Haals-αTfR-5 than with MV-F/H
(Figure 1D). These results indicate that the recombin-
ant Haals-αTfR-5 has a fusion activity in HFL-1 cells as
well as in HT1080 cells.Comparison of MMCT efficiency between different
protocols
To evaluate the ability of the method of Haals-αTfR-5-
mediated microcell fusion, we compared the efficiency
of MMCT on three different protocols, namely PEG-
induced, H protein (H)-mediated, or Haals-αTfR-mediated
microcell fusion. Three CHO cell line donors for each
protocol were used, with CHO/21HAC2, for PEG;
CHO4H6.1 M [19], for H protein; CHO/21HAC2/TfR,
for Haals-αTfR. Microcells were prepared from these
donor cells under standard conditions by using colce-
mid and cytochalasin B, followed by microcell fusion
with either HT1080 or HFL-1. MMCT efficiencies were
determined as the number of EGFP-positive colonies
which emerged under the selective culture condition in
the presence of Bsd because all donor cells carried
21HAC2 containing both EGFP and Bsd resistant genes.
Haals-αTfR-mediated fusion protocol is efficacious in
MMCT to HFL-1, whereas H protocol obtained the
Table 1 Comparison of MMCT efficiency between
different protocols
Recipient cell exp. Number of GFP(+) colonies
PEG H Haals-αTfR
HFL-1 1 2 3 13
2 N/T 6 12
3 N/T 1 10
4 N/T 4 17
HT1080 1 15 95 215
2 N/T 86 152
N/T; not tested.
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as low as with PEG in one experiment (Table 1). In the
case of HT1080, susceptible to H protocol, the Haals-
αTfR protocol exhibited comparable or even greater
effectiveness. Furthermore, transient expression of MV-
F/Haals-αTfR provided about the same number of
EGFP-positive colonies as stable expression from CHO/
21HAC2/TfR (Figure 1E). These results demonstrate
that retargeting of microcell fusion using Haals-αTfR could



































Figure 2 Construction of the iHAC for reprogramming human somatic cel
expression cassettes for multi copies of a set of four reprogramming factor
human P53shRNA construct and DsRed (R). (B) Expression of the four repro
qRT-PCR. Transcript levels of transgenes were standardized to Gapdh. Trans
mp25. Error bars, s. d. (C) FISH analysis of CHO/iHAC/X53. Digoxigenin-labeled
Biotin-labeled pPAC-2CAG-O2hP53sh (green) was used to detect the reprogra
with DAPI. White arrows indicate the iHAC vector and the insets show enlargcompared with PEG or original MV fusogen, and more
convenient preparation of retargeted microcells could be
achieved by transient transfection without establishment of
a stable clone expressing the retargeted MV-H.Capability of Haals-αTfR-mediated microcell fusion to
introduce a HAC vector to human fibroblasts
To determine whether Haals-αTfR-mediated microcell
fusion could be applied to transfer more functional,
elaborate HAC vectors to human normal cells, we next
tried human cell reprogramming by the introduction of
a HAC vector via Haals-αTfR-mediated microcell fusion.
The HAC vector was constructed by minor modification
of iHAC2, which enables reprogramming of mouse em-
bryonic fibroblasts to pluripotency [25], and to change
mouse p53-knockdown construct into a human version
(Figure 2A). The CHO cell donor clone exhibited stable
and comparable expression of four factors as with CHO/
iHAC2/mp25 cells and was designated CHO/iHAC/X53
(Figure 2B). FISH analysis showed that the HAC vector
was maintained independently from the host chromo-
somes in CHO/iHAC/X53 (Figure 2C). Then, MMCT













ls. (A) Schematic diagram of the iHAC/X53. iHAC/X53 is carrying the
s (2 copies of Klf4, c-Myc and Sox2, and also 4 copies of Oct4), a
gramming factors contained in the iHAC vectors was confirmed by
cript levels in CHO/iHAC/X53 were compared to levels in CHO/iHAC2/
alphoid satellite marker (red) was used to detect the HAC backbone.
mming cassette in the iHAC. Chromosomal DNA was counterstained
ed images of the iHAC.
Table 2 Summary of MMCT experiments to introduce iHAC into HFL-1
recipient MMCT exp. # of GFP(+) colonies Dedifferentiated clone name
D8-11* D20-35* D47-50*
HFL-1 PEG 1 9 1 0
Haals-αTFR 1 N/D 26 24 (3) hA-1, 8, 9
2 15 5 3 (1) hB-22
3 25 3 2 (2) hC-10, 29
4 29 11 7 (1) hD-8
5 26 14 7 (2) hE-10, 25
N/D; not determined, *; days after MMCT, values in parentheses denote the number of dedifferentiated clones.
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F/Haals-αTfR in these donor cells. As seen in 21HAC2,
iHAC was more efficiently transferred into HFL-1 by
using the retargeted MV fusogen than PEG fusion from
the objective of EGFP fluorescence (Table 2). A total 59
clones were obtained from 5 experiments about a month
after MMCTs and 43 out of 59 clones were expandable up
to 47 days after MMCT. Remarkably, 19% of expandable
clones (9 of 43) could continue proliferating further over

















Figure 3 Introduction of the iHAC to HFL-1 by MV-MMCT using Haals-αTfR
colony. Three dedifferentiated clones (h-A9-3, h-A2 and h-A8) exhibited do
morphology. (B) Expression of exogenous reprogramming factors detected
internal control. (C) FISH analysis of EGFP(+) clone. Digoxigenin-labeled alp
and endogenous chromosomes 13 and 21. Biotin-labeled pPAC-2CAG-O2h
iHAC. Chromosomal DNA was counterstained with DAPI. White arrows indi
Arrowheads indicate Chr.13 or 21.colonies resulting from tight cell-to-cell association,
whereas residual clones with fibroblast-like feature grad-
ually ceased cell proliferation (Figure 3A and Additional
file 1 Figure S1). This result indicated that iHAC could
dedifferentiate human fibroblasts. To assess the func-
tion of iHAC in dedifferentiation, three representative
clones, h-A2, h- A8 and h-A9 subclone 3 (h-A9-3), were
further analyzed. FISH analysis and semi-quantitative
RT-PCR analysis indicated that all of these clones


























. (A) Representative bright-field and fluorescence images of an EGFP(+)
om-like morphology, whereas a clone h-D20 still retained fibroblast-like
by RT-PCR in EGFP(+)/dedifferentiated clones. NAT1 was used as an
hoid satellite marker (red) was used to detect the HAC backbone
P53sh (green) was used to detect the reprogramming cassette in the
cate iHAC vector and the insets show enlarged images of the iHACs.
Hiratsuka et al. BMC Biotechnology  (2015) 15:58 Page 7 of 8chromosomes and consistently expressed four exogen-
ous transgenes, constructed in the iHAC, as well as an
EGFP gene (Figure 3B and C). Furthermore, the expres-
sion of endogenous pluripotent markers (SOX2 and
TERT) was significantly induced in all clones, in addition
to slight induction of endogenous OCT4 (Additional file 1
Figure S2). These results suggested that MMCT mediated
by retargeted MV fusogen could introduce HACs into
human normal cells in excellent condition without
recognizable aberrations and that all of the transgenes
harbored in the HAC were efficiently transcribed
enough to fulfill their functions.
Discussion
We demonstrate that the alteration of the tropism of
MV-H protein by fusing anti-TfR scFv at its C terminus
is applicable to microcell fusion. This retargeted MV-H
successfully induced fusion between microcells and hu-
man fibroblast HFL-1 (Figure 3 and Additional file 1
Figure S1), which was moderately hard to be recognized
by original MV-H protein. These results indicate that
retargeting strategy of the H protein is available for micro-
cell fusion as well as original H protein, leading to expan-
sion of the spectrum of target cells to which a HAC vector
can be transferred. Since human normal cells, e.g. fibro-
blasts and mesenchymal stem cells, show less efficiency of
microcell fusion by PEG than malignant cells, microcell
fusion mediated by MV-derived fusion machinery is an at-
tractive technique for gene delivery which involves the
transfer of a HAC vector from a donor cell to human nor-
mal cells [14,19,34]. However, the number of GFP-positive
colonies yielded from HFL-1 by retargeted MV-MMCT
was approximately one tenth of that from HT1080, even
though TfR was expressed on cell surface at an equiva-
lent level in both cell lines (Figure 1A and Table 1). This
difference in efficiency may be due to predisposition to-
ward cellular quiescence of HFL-1 rather than HT1080,
because many GFP-positive HFL-1 cells were detected
on the day following retargeted MV-MMCT (data not
shown). Indeed, in the case of iHAC introduction into
HFL-1, the number of GFP-positive colonies gradually
decreased from the early stage (D8-11) to the later stage
(D47-50) (Table 2).
Additionally, it remains to be elucidated whether MV-
mediated microcell fusion affects physiological func-
tionality of transgenes carried on HACs; except for a
drug-resistant gene and an EGFP gene, transgenes have
not been assessed for their expressions or gene functions
after MV-mediated microcell fusion. Here we demon-
strated that transgenes of Klf-4, c-Myc, Sox2, and Oct4,
were persistently expressed in EGFP-positive, iHAC-
retained fibroblast clones over three months, and some
of these clones exhibited dedifferentiated phenotypes:
potent growth ability, marked change of cell morphology,and activation of endogenous pluripotency-related genes
(Figure 3 and Additional file 1 Figure S2). Furthermore,
pluripotent cells were derived from one of the dedifferen-
tiated clones during further prolonged culture, resulting
from elimination of transgene expression by spontaneous
loss of iHAC (Additional file 1 Figure S3). These results
were consistent with our previous study of reprogram-
ming of mouse embryonic fibroblasts which received
iHAC2 by PEG-induced microcell fusion [25]. Taken
together, it can be said that MV-derived fusion machiner-
ies exhibit no influence on not only expression of trans-
genes carried on HACs, but on overall functions of HACs
themselves, identically thus to PEG-induced fusion.Conclusions
In this study, we demonstrated that MV-H protein, retar-
geted by adding anti-TfR scFvs, yielded the expansion of
cell range applicable for gene transfer via HAC vectors
without perturbation of HAC functions. So far, we have
demonstrated the following advantages of HAC vector
systems for gene transfer over others: no size limitation
of inserted genes, persistent and stable expression of
these genes, and no scar in the host genome. Therefore,
we anticipate that this technology applying MV fusogen
will facilitate the systematic cell engineering by HACs
for modification of a variety of cell types, such as repro-
gramming cells.Additional file
Additional file 1: Figure S1. Bright-field and fluorescence images of
dedifferentiated EGFP(+) clones. Figure S2. Expression of pluripotency
markers detected by RT-PCR in dedifferentiated clones. Figure S3.
Establishment of iHAC-free human iPS cells. Table S1. Anti-TfR mAbs for
cloning scFv-expressing vectors. Table S2. Primers used for PCR analysis.
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